NO921364D0 - Hybridpolypeptid - Google Patents

Hybridpolypeptid

Info

Publication number
NO921364D0
NO921364D0 NO921364A NO921364A NO921364D0 NO 921364 D0 NO921364 D0 NO 921364D0 NO 921364 A NO921364 A NO 921364A NO 921364 A NO921364 A NO 921364A NO 921364 D0 NO921364 D0 NO 921364D0
Authority
NO
Norway
Prior art keywords
hybrid
Prior art date
Application number
NO921364A
Other languages
English (en)
Other versions
NO921364L (no
Inventor
Dean Ervin Cress
Ferdinand Carl Haase
Original Assignee
Rohm & Haas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rohm & Haas filed Critical Rohm & Haas
Publication of NO921364D0 publication Critical patent/NO921364D0/no
Publication of NO921364L publication Critical patent/NO921364L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/675—Beta-endorphins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1018—Carboxy- and carbamoyl transferases (2.1.3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO92921364A 1991-04-19 1992-04-08 Hybridpolypeptid NO921364L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/687,819 US6072039A (en) 1991-04-19 1991-04-19 Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest

Publications (2)

Publication Number Publication Date
NO921364D0 true NO921364D0 (no) 1992-04-08
NO921364L NO921364L (no) 1992-10-20

Family

ID=24761988

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92921364A NO921364L (no) 1991-04-19 1992-04-08 Hybridpolypeptid

Country Status (13)

Country Link
US (1) US6072039A (no)
EP (1) EP0511747A1 (no)
JP (1) JPH06166698A (no)
KR (1) KR920019820A (no)
AU (1) AU659139B2 (no)
BR (1) BR9201437A (no)
CA (1) CA2064933A1 (no)
FI (1) FI921740L (no)
IE (1) IE921250A1 (no)
IL (1) IL101454A0 (no)
MX (1) MX9201749A (no)
NO (1) NO921364L (no)
NZ (1) NZ242395A (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
WO1996021156A1 (en) * 1995-01-04 1996-07-11 Abbott Laboratories Method for preparing scintillation proximity assay targets
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
EP0985931A3 (en) * 1998-09-04 2000-03-29 Becton Dickinson and Company Recombinant antigen immunoassay for the diagnosis of syphilis
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK1842002A3 (en) 1999-08-09 2003-09-11 Lexigen Pharm Corp A fusion protein, a multi-function protein complex, a multi-function fusion protein, a nucleic acid, a cell, their use, method for preparing a fusion protein and method of targeting cytokines
DE19952956A1 (de) 1999-11-03 2001-05-17 Acgt Progenomics Ag Verfahren zur Verbindung von molekularen Substanzen
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
MXPA02012734A (es) 2000-06-29 2003-04-25 Merck Patent Gmbh Mejoramiento de las respuestas inmunes mediadas por la proteina de fusion anticuerpo-citocina, mediante tratamiento combinado con agentes mejoradores de la captacion de inmunocitocina.
US20020142355A1 (en) * 2000-11-14 2002-10-03 Baylor College Of Medicine Methods for the in vivo biotin labeling of polypeptides
PT1366067E (pt) 2001-03-07 2012-11-29 Merck Patent Gmbh Tecnologia de expressão para proteínas contendo uma unidade de anticorpo de isotipo híbrido
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
PL205352B1 (pl) 2001-05-03 2010-04-30 Merck Patent Gmbh Rekombinowane przeciwciało specyficzne dla nowotworu
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
AU2002363961A1 (en) * 2001-12-05 2003-06-23 Kentucky Bioprocessing, Llc Flexible method and apparatus for high throughput production and purification of multiple proteins
GB0202018D0 (en) 2002-01-29 2002-03-13 Sense Proteomic Ltd Tag and method
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
CN100432105C (zh) 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
AU2004262640B2 (en) 2003-06-16 2010-12-23 Ucb Manufacturing, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
AU2004309050B2 (en) 2003-12-30 2010-10-14 Merck Patent Gmbh IL-7 fusion proteins
ES2387028T3 (es) 2003-12-31 2012-09-12 Merck Patent Gmbh Proteína de fusión de Fc-eritropoyetina con farmacocinética mejorada
DE602005016773D1 (de) 2004-01-22 2009-11-05 Merck Patent Gmbh Antikrebs-antikörper mit reduzierter komplementfixierung
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
ATE465176T1 (de) 2004-12-09 2010-05-15 Merck Patent Gmbh Il-7-varianten mit reduzierter immunogenität
DE102005040347A1 (de) 2005-08-25 2007-03-01 Profos Ag Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von Listerien
CN101351477B (zh) 2005-12-30 2011-11-16 默克专利有限公司 具有降低的免疫原性的抗cd19抗体
PT1966238E (pt) 2005-12-30 2012-07-31 Merck Patent Gmbh Uso de hsp70 como um regulador de atividade enzimática
EP2275816A3 (en) 2006-03-22 2011-06-29 Viral Logic Systems Technology Corp. Methods for identifying polypeptide targets and uses thereof for treating immunological diseases
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CN101855242B (zh) 2007-09-14 2014-07-30 阿迪马布有限责任公司 合理设计的合成抗体文库及其用途
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
BRPI1016204A2 (pt) 2009-04-22 2016-04-19 Merck Patent Gmbh proteínas de fusão de anticorpos com sítios de ligação fcrn modificados
EP2527431A1 (en) 2011-05-26 2012-11-28 bioMérieux S.A. Novel Listeria bacteriophage tailspike protein and uses thereof
US20150099860A1 (en) * 2013-10-08 2015-04-09 Proteins Easy Corp Methods for separating and purifying endogenous, exogenous and recombinant proteins/peptides from plants and animals using aqueous-free, anhydrous strategies
CN106156530A (zh) * 2016-08-03 2016-11-23 北京好运到信息科技有限公司 基于栈式自编码器的体检数据分析方法及装置

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839293A (en) * 1986-02-24 1989-06-13 The Trustees Of Columbia University In The City Of New York DNA encoding streptavidin, streptavidin produced therefrom, fused polypeptides which include amino acid sequences present in streptavidin and uses thereof
AU2635088A (en) * 1987-12-04 1989-06-08 Du Pont Merck Pharmaceutical Company, The Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension
WO1989009393A1 (en) * 1988-03-24 1989-10-05 Igen, Inc. Luminescent chimeric proteins
AU647025B2 (en) * 1989-05-19 1994-03-17 Biotechnology Research And Development Corporation Fusion proteins having an in vivo post-translational modification site and methods of manufacture and purification
EP0711303B2 (en) * 1993-07-30 2009-06-10 Affymax, Inc. Biotinylation of proteins

Also Published As

Publication number Publication date
FI921740A0 (fi) 1992-04-16
CA2064933A1 (en) 1992-10-20
FI921740A7 (fi) 1992-10-20
AU659139B2 (en) 1995-05-11
NO921364L (no) 1992-10-20
BR9201437A (pt) 1992-12-01
MX9201749A (es) 1992-10-01
KR920019820A (ko) 1992-11-20
EP0511747A1 (en) 1992-11-04
AU1398792A (en) 1992-10-22
JPH06166698A (ja) 1994-06-14
IE921250A1 (en) 1992-10-21
IL101454A0 (en) 1992-12-30
US6072039A (en) 2000-06-06
FI921740L (fi) 1992-10-20
NZ242395A (en) 1993-12-23

Similar Documents

Publication Publication Date Title
NO921364D0 (no) Hybridpolypeptid
ATE137279T1 (de) Stoffauflauf
FI933434A0 (fi) Fast fasanalys
DE59207765D1 (de) Fahrzeug
ATA131391A (de) Reibring
FI923342L (fi) Pleuromutilinkomplex
FI921529L (fi) Vaetekrackningsfoerfarande
FI925295L (fi) Baenksystem foer kompositioner avsedda foer jordbruk
DE69215896D1 (de) Hybrid-flugzeug
ATA170491A (de) Mauerstein
ATA39792A (de) Maehwerk
ATE163916T1 (de) Ethyl-6-formyloxy-4-hexenoat
ATA9892A (de) Formstein
ATA62591A (de) Ladegerät
FI930531A0 (fi) Hybrid a-amylaspromotorer
PT8318T (pt) Veiculo lanca-pontes
KR930010863U (ko) 자동차의 소제구
LV5577A3 (lv) Nootrops lidzeklis
FI915798L (fi) Harpa
KR940000228U (ko) 재치대
BR7100443U (pt) Vigier
BR9100002A (pt) Candress
ATA23591A (de) Muenzkassa
ATA235591A (de) Eluiergeraet
ATA188391A (de) Alpinski